Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2019-06-15
2036-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement Registry
NCT02394184
The Asian Transcatheter Aortic Valve Replacement Registry
NCT02308150
Long-term Prognosis and Valve Durability of TAVR
NCT06379386
Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
NCT06381271
TAVR for Aortic Valve Disease
NCT05439863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Korea Centers
Seoul, Korea All Patients undergoing TAVR
TAVR
transcatheter aortic valve replacement (TAVR)
Stanford University
California, USA All Patients undergoing TAVR
TAVR
transcatheter aortic valve replacement (TAVR)
Northwestern University
Evanston, Illinois, USA All Patients undergoing TAVR
TAVR
transcatheter aortic valve replacement (TAVR)
Cheng-Hsin Hospital
Taipei, Taiwan All Patients undergoing TAVR
TAVR
transcatheter aortic valve replacement (TAVR)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAVR
transcatheter aortic valve replacement (TAVR)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duk-Woo Park, MD
OTHER
CardioVascular Research Foundation, Korea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Duk-Woo Park, MD
Professor, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan Ching Yuen Yeung, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
James D. Flaherty, MD
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Stanford, California, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Second Affiliated Hospital of Zhejiang University
Hangzhou, , China
Bucheon Sejong Hospital
Bucheon-si, , South Korea
Chungnam National University Hospital
Daejeon, , South Korea
Asan Medical Center
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alan Ching Yuen Yeung, MD
Role: primary
James D. Flaherty, MD
Role: primary
Jian-an Wang, MD
Role: primary
Jae-hyung Park, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Kim M, Kang DY, Ahn JM, Kim JB, Yeung AC, Nishi T, Fearon WF, Cantey EP, Flaherty JD, Davidson CJ, Malaisrie SC, Kim HJ, Lee J, Park J, Kim H, Cho S, Choi Y, Park SJ, Park DW. Sex-Specific Disparities in Clinical Outcomes After Transcatheter Aortic Valve Replacement Among Different Racial Populations. JACC Asia. 2024 Feb 13;4(4):292-302. doi: 10.1016/j.jacasi.2023.11.016. eCollection 2024 Apr.
Kim H, Kang DY, Ahn JM, Kim JB, Yeung AC, Nishi T, Fearon WF, Cantey EP, Flaherty JD, Davidson CJ, Malaisrie SC, Kim N, Kim M, Lee J, Park J, Choi Y, Park SJ, Park DW. Race-Specific Impact of Conventional Surgical Risk Score on 1-Year Mortality After Transcatheter Aortic Valve Replacement. JACC Asia. 2023 Feb 28;3(3):376-387. doi: 10.1016/j.jacasi.2022.11.007. eCollection 2023 Jun.
Kang DY, Ahn JM, Kim JB, Yeung A, Nishi T, Fearon W, Cantey EP, Flaherty JD, Davidson CJ, Malaisrie SC, Park SY, Yun SC, Ko E, Park H, Lee SA, Kim DH, Kim HJ, Kim JB, Choo SJ, Park DW, Park SJ. Inter-racial differences in patients undergoing transcatheter aortic valve implantation. Heart. 2022 Sep 12;108(19):1562-1570. doi: 10.1136/heartjnl-2021-320364.
Park H, Ahn JM, Kang DY, Kim JB, Yeung AC, Nishi T, Fearon WF, Cantey EP, Flaherty JD, Davidson CJ, Malaisrie SC, Kim S, Yun SC, Ko E, Lee SA, Kim DH, Kim HJ, Kim JB, Choo SJ, Park DW, Park SJ. Racial Differences in the Incidence and Impact of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2021 Dec 27;14(24):2670-2681. doi: 10.1016/j.jcin.2021.08.038. Epub 2021 Nov 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMCCV2019-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.